The first peptide polyagonist that was officially approved for T2DM and obesity was tirzepatide (LY3298176), a dual GLP-1/GIP receptor agonist which is currently under investigation in RCTs for obesity and NAFLD [7]. The gene discussed is GCG; the disease is obesity disorder.